Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-sequence Study of the Effect of Belatacept on the Pharmacokinetics of Caffeine, Losartan, Omeprazole, Dextromethorphan, and Midazolam Administered as "Inje Cocktail" in Healthy Subjects

NCT01766050 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT01766050
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01766050 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-sequence Study of the Effect of Belatacept on the Pharmacokinetics of Caffeine, Losartan, Omeprazole, Dextromethorphan, and Midazolam Administered as "Inje Cocktail" in Healthy Subjects
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2013
Completion date
April 30, 2013
Enrollment
45 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

transplant rejection